TristelTSNLF +6.35%97 EBITDA Margin % is 26.13% as of Dec. 2025, which is 10% above its 10-year median of 23.81. GuruFocus rates TSNLF with a GF Score™ of 97/100 and a GF Value™ of $6.13 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, Tristel ranks better than 86.4% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tristel's EBITDA for the
six
months ended in Dec. 2025 was $8.97 Mil. Tristel's Revenue for the
six
months ended in Dec. 2025 was $34.34 Mil. Therefore, Tristel's EBITDA margin for the quarter that ended in Dec. 2025 was 26.13%.
Tristel (OTCPK:TSNLF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tristel EBITDA Margin % Related Terms
Tristel EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tristel's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSNLF vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Tristel's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tristel's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tristel (TSNLF) has a EBITDA Margin % of 26.13% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tristel and its competitors. This is 10% above median its historical median of 23.81. Over the past decade, Tristel's EBITDA Margin % has ranged from 21.42 to 29.56. According to the industry distribution chart, Tristel ranks #111 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 13.6%.
Is Tristel's EBITDA Margin % too high?
Tristel's current EBITDA Margin % of 26.13% is 10% above median its 10-year median of 23.81. Over the past 10 years, this metric has ranged from a low of 21.42 to a high of 29.56. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Tristel's value of 26.13% is 249.6% above this industry median. Based on the distribution chart, Tristel ranks #111 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tristel has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tristel's EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #111 out of 816 companies for EBITDA Margin %. This places Tristel in the top 14% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Tristel's value of 26.13% is 249.6% above this benchmark. Historically, Tristel's own EBITDA Margin % has ranged from 21.42 to 29.56 over the past decade. While the company's 10-year median is 23.81 vs. the industry median of 7.48, Tristel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current EBITDA Margin % of 26.13% is 249.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tristel and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current EBITDA Margin % is 26.13%, which is 10% above median its own 10-year median of 23.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.13, compared to a current price of $5.53 — trading 9.8% below its estimated fair value. The current EBITDA Margin % is 26.13%, which is 10% above median its 10-year median of 23.81 and 249.6% above the Medical Devices & Instruments industry median of 7.48. Tristel's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tristel (TSNLF), the current EBITDA Margin % is 26.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.53 is trading 9.8% below its estimated GF Value™ of $6.13.
GuruFocus considers Tristel to be Modestly Undervalued.
Key valuation signals for TSNLF:
EBITDA Margin %: 26.13% (10% above median its 10-year median of 23.81)
GF Value™: $6.13 vs. price of $5.53 (9.8% below fair value)
Industry Position: 249.6% above the Medical Devices & Instruments median (#111 of 816)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
97GF Score
Get the complete analysis for TSNLF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
